v3.26.1
Collaboration and License Agreements - Visirna Therapeutics Inc. (“Visirna”) and Genzyme Corporation (“Sanofi”) (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Aug. 01, 2025
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Sep. 30, 2025
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue   $ 75,253   $ 27,767 $ 413,023 $ 572,976  
Accounts receivable   8,556     8,556   $ 6,824
Sanofi | Sanofi License Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Initial transaction price $ 130,000            
Triggered milestone payments     $ 10,000        
Future potential milestone payments 255,000            
Fixed consideration $ 130,000            
Revenue   1,200     12,000    
Accounts receivable   $ 800     $ 800